Targeting MASLD and MASH in the US Hispa...

Interview with Robert Bals, MD, PhD, author of Azelastine Nasal Spray for Prevention of SARS-CoV-2 Infections: A Phase 2 Randomized Clinical Trial, and Dan H. Barouch, MD, PhD, author of A Novel Approach for Preventing Respiratory Virus Infections. Hosted by Eve Rittenberg, MD. R ... Show More

Interview with Alison J. Huang, MD, MAS, and Stephanie Faubion, MD, MBA, authors of Nonhormonal Treatment of Menopausal Vasomotor Symptoms. Hosted by Eve Rittenberg, MD. Related Content: Nonhormonal Treatment of Menopausal Vasomotor Symptoms 

JAMA Internal Medicine fellows Jerard Z. Kneifati-Hayek, MD, MS, Ilana B. Richman, MD, MHS, and Nathan Stall, MD, PhD, discuss their experiences learning how to work as members of the editorial team at a leading, widely read, high-impact internal medicine journal. They explore ke ... Show More

Interview with Bradley J. Katz, MD, PhD, author of Ophthalmic Complications Associated With the Antidiabetic Drugs Semaglutide and Tirzepatide. Hosted by Neil Bressler, MD. Related Content: Ophthalmic Complications Associated With the Antidiabetic Drugs Semaglutide and Tirzepatid ... Show More

Contributor: Travis Barlock MD Educational Pearls: How do you differentiate between compensated and decompensated cirrhosis? Use the acronym VIBE to look for signs of being decompensated. V-Volume Cirrhosis can cause volume overload through a variety of mechanisms such as by incr ... Show More

By the end of this episode you will be able to: Describe the anatomy and physiology of the liver Outline the pathophysiology and common symptoms of liver failure Explain how to assess and treat a patient with cirrhosis 

Featuring articles on PI3K-altered colorectal cancer, type 2 diabetes, oral semaglutide, and proportional-assist ventilation; a review article on tumor lysis syndrome; a case report of a girl with chest pain and bone and liver lesions; and Perspectives on integrating pharmacother ... Show More

Non-alcoholic fatty liver disease (NAFLD) presents as a disease spectrum. Fatty change is a common and frequently benign condition, present in 20-30% of the population and up to 90% of the morbidly obese. This Essential Knowledge Update (EKU2017.1) podcast explores the NICE guide ... Show More

An analysis of the IRIS® Registry shows IOL exchanges are increasing over time with vision improving 60% of the time, but worse visual outcomes associated with greater age, worse baseline vision, Black race, Hispanic ethnicity, Medicaid insurance, smoking, and concurrent vitrecto ... Show More

Most SLPs we know can count on one hand (…or one finger!?) the number of times they learned about the liver in grad school. But when it comes to our role in cognitive-communication disorders, liver disease can be a main cause — and something you absolutely should be familiar with ... Show More

Fatty liver disease, encompassing both non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD), is a prevalent condition in the United States. NAFLD affects approximately 24% of U.S. adults, translating to about 80 million individuals. Within this group, a sub ... Show More

Kristin Kirkpatrick, MS, RDN, renowned dietitian from the Cleveland Clinic and author of Skinny Liver and Regenerative Health explains why the liver is critical to health, and how Non-Alcoholic Fatty Liver Disease is a silent killer that has become an epidemic.  With an estimated ... Show More

Exertional heat illness at its extreme may cause heat stroke and altered mental status (confusion, delirium, stupor, or unconsciousness), which can result in organ failure and death. Author Francis G. O’Connor, MD, MPH, discusses heat-related illness in athletes, including risk f ... Show More